Emerging oral drugs for relapsing-remitting multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic inflammatory central nervous system (CNS) disease, traditionally viewed as autoimmune and demyelinating.
• Current disease-modifying drugs (DMDs) for MS include five first-line and two second-line treatments, but often present suboptimal efficacy and side effects, impacting patient adherence.
• The inconvenience of long-term injectable or parenteral MS therapies highlights the need for improved patient satisfaction and adherence through new strategies.

Purpose of the Study:

• To review emerging oral therapies for relapsing-remitting multiple sclerosis (MS).
• To evaluate the potential of these new oral treatments to improve patient adherence and therapeutic outcomes.
• To discuss the comparative efficacy and tolerability of oral versus injectable MS medications.

Main Methods:

• Review of five oral therapies in Phase III development or recently approved for relapsing-remitting MS.
• Inclusion of cladribine, fingolimod, fumaric acid (BG-12), teriflunomide (A77126), and laquinimod (ABR-215062).
• Analysis of preliminary results regarding efficacy, tolerability, and patient adherence.

Main Results:

• Preliminary findings suggest oral MS medications are comparable or potentially superior to current injectable formulations.
• Improved outcomes are anticipated to lead to higher perceived efficacy and better patient adherence.
• The transition to oral therapies will involve balancing efficacy, tolerability, and patient compliance history.

Conclusions:

• Oral therapies represent a significant advancement in MS treatment, potentially improving patient satisfaction and adherence.
• Safety will be a critical factor in the future development and adoption of new MS drugs.
• The shift towards oral MS medications may optimize therapeutic outcomes by addressing limitations of current treatments.